EpimAb Files for HKEX IPO with Nearly USD 500m Post-Money Valuation

EpimAb Biotherapeutics has submitted a listing application to the Hong Kong Stock Exchange (HKEX). Founded in 2015, the clinical-stage biotech focuses on developing T-cell engagers (TCEs) for the treatment of cancer and autoimmune diseases. Its pipeline includes eight internally discovered assets, with its core product EMB-01 being an EGFR×cMET bispecific antibody (BsAb) in Phase II development for metastatic colorectal cancer (mCRC). The company has established multiple global out-licensing deals worth over USD 2.1 billion, ranking it second globally in TCE collaborations by value.

Prior to the IPO filing, the company completed several funding rounds, with a post-money valuation approaching USD 500 million in its most recent financing. Financially, EpimAb reported revenues of zero, RMB 458.9 million, RMB 428.7 million and RMB 91.7 million for 2023, 2024, and the nine months ended 30 September 2024 and 2025 respectively, all derived from licensing and collaboration agreements.

PharmCube's NextBiopharm® database lists seven transactions carried out by EpimAb between 2016 and 2025. Click here to request a free trial for NextBiopharm®.

Daily News
Hengrui Gains First Global Approval for Anti-PD-L1×TGF-βRII Bispecific
2026-01-12
Lilly Collaborates with InduPro on in Bs/MsAb Deal Worth Up to USD 950m
2026-01-12
HemaCell Secures Additional Funding in Series B1 Within a Week
2026-01-06
MSD Wins China Approval for First-in-Class PAH Drug Sotatercept
2026-01-06
Doer Bio's GLP-1R/GCGR/FGF21R Agonist Granted BTD in China
2026-01-05
Latest Report
Insights into China’s Innovative Drug R&D and Transaction Trends_PharmCube
Details